Skip to content
DraconiticResearch
Search Sources API
210,423 studies31 sourcesUpdated 2 min ago
Peer-reviewedCC BY-NC-NDTranslational andrology and urology

The role of the p53 signaling pathway in prostate cancer.

  • Rui Shi1
  • Hongbing Fu2
  • Xinye Wang1
  • Changyi Ye1
  • Xinyun Ji1
  • Haonan Zhao1
  • Yuyan Zhang1
  • Dihui Fan3
  1. 1School of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
  2. 2School of Second Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
  3. 3Department of Traditional Chinese Medicine, Jiaxing Maternity and Child Health Care Hospital, Jiaxing Women and Children's Hospital, Wenzhou Medical University, Jiaxing, China.
Read full textPDFDOICite

Abstract

The p53 signaling pathway is pivotal for maintaining genomic stability and regulating cell fate, playing a critical role in the initiation, progression, and treatment resistance of prostate cancer (PCa). This review provides a comprehensive overview of the p53 pathway's structure and function, with emphasis on the distribution characteristics and clinical implications of TP53 mutations in PCa. We systematically examine how these mutations correlate with disease aggressiveness, therapeutic resistance, and patient prognosis. In particular, the article delves into the mechanisms by which inactivation of the p53 pathway drives immune evasion, metabolic reprogramming, and alterations in the tumor microenvironment. We also highlight the synergistic interactions between p53 alterations and other key molecular events, including TMPRSS2-ERG fusion and PTEN loss, which together form a PCa-specific regulatory network that accelerates carcinogenesis and promotes lineage plasticity. Furthermore, the review discusses the emerging role of mutant p53 in shaping the immunosuppressive microenvironment and metabolic adaptations that underlie resistance to androgen deprivation therapy, radiotherapy, and chemotherapy. Finally, we address potential strategies and research challenges in targeting the p53 pathway for PCa treatment, including the development of small molecule reactivators, synthetic lethal approaches, and biomarker-directed combination therapies. This review offers a theoretical foundation and guidance for future basic research and clinical applications aimed at improving outcomes for patients with PCa.

Related

  1. JARID2 promotes prostate cancer progression associated with TET3-mediated activation of the FAK/PI3K/AKT signaling pathway
    Jinrun Wang, Yang Liu, Yanze Li +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  2. DUSP13 promotes prostate cancer progression by regulating the ERK1/2 pathway
    Translational andrology and urologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer
    Varun Nandakumar, Georges Gebrael, Neeraj Agarwal
    The OncologistPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  4. A Multi-Kinase Inhibitor Screen Identifies mTOR Signaling as a Vulnerability in Advanced Prostate Cancer.
    Sriya Sridhar, Kabhilan Mohan, Smitha Kizhake +3
    bioRxivPreprintAll rights reservedFull textOncologybioRxivPMC
  5. Molecular stratification of SPOP-mutant prostate cancer demonstrates Wnt signaling and replication stress signatures in diverse patient populations
    Kinza Rizwan, Sai Prasada Rao Manikonda, Heidi Dowst +8
    Cell ReportsPeer-reviewedCC BY 4.0General medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{shi2026role,
  title = {{The role of the p53 signaling pathway in prostate cancer.}},
  author = {Rui Shi and Hongbing Fu and Xinye Wang and Changyi Ye and Xinyun Ji and Haonan Zhao and Yuyan Zhang and Dihui Fan},
  journal = {Translational andrology and urology},
  year = {2026},
  month = sep,
  doi = {10.21037/tau-2026-0645},
  url = {https://europepmc.org/article/MED/42997210},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - The role of the p53 signaling pathway in prostate cancer.
AU  - Rui Shi
AU  - Hongbing Fu
AU  - Xinye Wang
AU  - Changyi Ye
AU  - Xinyun Ji
AU  - Haonan Zhao
AU  - Yuyan Zhang
AU  - Dihui Fan
PY  - 2026
DA  - 2026/09/29
JO  - Translational andrology and urology
DO  - 10.21037/tau-2026-0645
UR  - https://europepmc.org/article/MED/42997210
AB  - The p53 signaling pathway is pivotal for maintaining genomic stability and regulating cell fate, playing a critical role in the initiation, progression, and treatment resistance of prostate cancer (PCa). This review provides a comprehensive overview of the p53 pathway's structure and function, with emphasis on the distribution characteristics and clinical implications of TP53 mutations in PCa. We systematically examine how these mutations correlate with disease aggressiveness, therapeutic resistance, and patient prognosis. In particular, the article delves into the mechanisms by which inactivation of the p53 pathway drives immune evasion, metabolic reprogramming, and alterations in the tumor microenvironment. We also highlight the synergistic interactions between p53 alterations and other key molecular events, including TMPRSS2-ERG fusion and PTEN loss, which together form a PCa-specific regulatory network that accelerates carcinogenesis and promotes lineage plasticity. Furthermore, the review discusses the emerging role of mutant p53 in shaping the immunosuppressive microenvironment and metabolic adaptations that underlie resistance to androgen deprivation therapy, radiotherapy, and chemotherapy. Finally, we address potential strategies and research challenges in targeting the p53 pathway for PCa treatment, including the development of small molecule reactivators, synthetic lethal approaches, and biomarker-directed combination therapies. This review offers a theoretical foundation and guidance for future basic research and clinical applications aimed at improving outcomes for patients with PCa.
SN  - 2223-4691
ER  -